Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Non Operating Income (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Non Operating Income over the past 9 years, most recently at -$156000.0 for Q4 2023.

  • For Q4 2023, Non Operating Income fell 106.55% year-over-year to -$156000.0; the TTM value through Dec 2023 reached -$202787.0, down 115.25%, while the annual FY2024 figure was $4.1 million, 759.28% up from the prior year.
  • Non Operating Income for Q4 2023 was -$156000.0 at Corbus Pharmaceuticals Holdings, down from $218000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $12.2 million in Q4 2020 and troughed at -$921408.0 in Q3 2020.
  • A 5-year average of $1.5 million and a median of $200500.0 in 2023 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: soared 1901.54% in 2020 and later tumbled 5995.69% in 2022.
  • Year by year, Non Operating Income stood at $609550.0 in 2019, then soared by 1901.54% to $12.2 million in 2020, then crashed by 97.38% to $319372.0 in 2021, then skyrocketed by 645.35% to $2.4 million in 2022, then plummeted by 106.55% to -$156000.0 in 2023.
  • Business Quant data shows Non Operating Income for CRBP at -$156000.0 in Q4 2023, $218000.0 in Q3 2023, and $183000.0 in Q2 2023.